Cargando…

Canagliflozin Improves Erythropoiesis in Diabetes Patients with Anemia of Chronic Kidney Disease

Background: We evaluated the erythropoietic effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, in type 2 diabetes patients with anemia of chronic kidney disease. Methods: Nine diabetes patients were enrolled and administered 100 mg canagliflozin once a day for 12 weeks. The patien...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maruyama, Takashi, Takashima, Hiroyuki, Oguma, Hidetaka, Nakamura, Yoshihiro, Ohno, Michiko, Utsunomiya, Kei, Furukawa, Tetsuya, Tei, Ritsukou, Abe, Masanori
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Mary Ann Liebert, Inc., publishers 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6875696/ https://www.ncbi.nlm.nih.gov/pubmed/31385724 http://dx.doi.org/10.1089/dia.2019.0212

Ejemplares similares

Prevalence of Zinc Deficiency in Japanese Patients on Peritoneal Dialysis: Comparative Study in Patients on Hemodialysis
por: Shimizu, Satoshi, et al.
Publicado: (2020)

Randomized Controlled Trial of Darbepoetin α Versus Continuous Erythropoietin Receptor Activator Injected Subcutaneously Once Every Four Weeks in Patients with Chronic Kidney Disease at the Pre-Dialysis Stage
por: Furukawa, Tetsuya, et al.
Publicado: (2015)

Prevalence of Carnitine Deficiency and Decreased Carnitine Levels in Patients on Peritoneal Dialysis
por: Shimizu, Satoshi, et al.
Publicado: (2019)

Oral Zinc Supplementation Reduces the Erythropoietin Responsiveness Index in Patients on Hemodialysis
por: Kobayashi, Hiroki, et al.
Publicado: (2015)

Zebrafish erythropoiesis and the utility of fish as models of anemia
por: Kulkeaw, Kasem, et al.
Publicado: (2012)

Significance of Levocarnitine Treatment in Dialysis Patients
por: Takashima, Hiroyuki, et al.
Publicado: (2021)

Chk1 Haploinsufficiency Results in Anemia and Defective Erythropoiesis
por: Boles, Nathan C., et al.
Publicado: (2010)

Treatment of renal anemia: Erythropoiesis stimulating agents and beyond
por: Biggar, Patrick, et al.
Publicado: (2017)

Tips for erythropoiesis-stimulating agent treatment of renal anemia
por: Tomosugi, Naohisa, et al.
Publicado: (2019)

Erythropoiesis-stimulating Agents and Anemia in Patients with Non-dialytic Chronic Kidney Disease
por: Kim, Sun Moon, et al.
Publicado: (2016)

The Use of Darbepoetin to Stimulate Erythropoiesis in the Treatment of Anemia of Chronic Kidney Disease in Dogs
por: Fiocchi, E.H., et al.
Publicado: (2017)

A critical role for mTORC1 in erythropoiesis and anemia
por: Knight, Zachary A, et al.
Publicado: (2014)

Factors associated with erythropoiesis-stimulating agent hyporesponsiveness anemia in chronic kidney disease patients
por: Amnuay, Kamalas, et al.
Publicado: (2019)

Factors Affecting Canagliflozin-Induced Transient Urine Volume Increase in Patients with Type 2 Diabetes Mellitus
por: Tanaka, Hiroyuki, et al.
Publicado: (2016)

Erythropoiesis-Stimulating Agents in the Management of Anemia in Chronic Kidney Disease or Cancer: A Historical Perspective
por: Aapro, Matti, et al.
Publicado: (2019)

Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia
por: Pashos, Chris L., et al.
Publicado: (2011)

Defective erythropoiesis in bone marrow is a mechanism of anemia in children with cancer.
por: Kim, MunHee, et al.
Publicado: (2002)

Pro-Inflammatory Cytokine-Mediated Anemia: Regarding Molecular Mechanisms of Erythropoiesis
por: Morceau, F., et al.
Publicado: (2009)

Protective roles of erythropoiesis-stimulating proteins in chronic heart failure with anemia
por: ZHOU, SHUQIN, et al.
Publicado: (2014)

NFAT-mediated defects in erythropoiesis cause anemia in Il2(−/−) mice
por: Giampaolo, Sabrina, et al.
Publicado: (2017)

A nano erythropoiesis stimulating agent for the treatment of anemia and associated disorders
por: Das, Monojit, et al.
Publicado: (2022)

Mechanisms of hemoglobin cycling in anemia patients treated with erythropoiesis-stimulating agents
por: Jörg, David J., et al.
Publicado: (2023)

Kinetics of Glucoregulatory Peptide Hormones during Hemodialysis with Cellulose Triacetate and Polysulfone Dialyzers in Patients with Diabetes and End-Stage Kidney Disease
por: Takao, Nobuteru, et al.
Publicado: (2023)

Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes
por: Matsutani, Daisuke, et al.
Publicado: (2018)

Renal, cardiovascular and safety outcomes of canagliflozin in patients with type 2 diabetes and nephropathy in East and South‐East Asian countries: Results from the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial
por: Wada, Takashi, et al.
Publicado: (2021)

Roxadustat treatment for erythropoiesis-stimulating agent-hyporesponsive anemia in maintenance hemodialysis patients
por: Song, Jie, et al.
Publicado: (2023)

Anemia and iron deficiency in COPD patients: prevalence and the effects of correction of the anemia with erythropoiesis stimulating agents and intravenous iron
por: Silverberg, Donald S, et al.
Publicado: (2014)

Rationale and design of oBservational clinical Research In chronic kidney disease patients with renal anemia: renal proGnosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetiN alfa (BRIGHTEN Trial)
por: Kato, Hideki, et al.
Publicado: (2017)

Efficacy and Safety of Canagliflozin in Kidney Transplant Patients
por: Shah, Mita, et al.
Publicado: (2019)

Effect of canagliflozin on the decline of estimated glomerular filtration rate in chronic kidney disease patients with type 2 diabetes mellitus: A multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group, phase III study in Japan
por: Wada, Takashi, et al.
Publicado: (2022)

Canagliflozin – Beginning of the journey
por: Pandey, Sunil Kumar, et al.
Publicado: (2014)

Phylogeny and Ontogeny of Erythropoiesis
por: Nunomura, Wataru, et al.
Publicado: (2015)

Iron deficient erythropoiesis might play key role in development of anemia in cancer patients
por: Park, Silvia, et al.
Publicado: (2015)

Hepcidin-Dependent Regulation of Erythropoiesis during Anemia in a Teleost Fish, Dicentrarchus labrax
por: Neves, João V., et al.
Publicado: (2016)

Effects of erythropoiesis-stimulating agents on heart failure patients with anemia: a meta-analysis
por: Zhang, Hengliang, et al.
Publicado: (2016)

The Interplay between Drivers of Erythropoiesis and Iron Homeostasis in Rare Hereditary Anemias: Tipping the Balance
por: Grootendorst, Simon, et al.
Publicado: (2021)

Effects of Exogenous Transferrin on the Regulation of Iron Metabolism and Erythropoiesis in Iron Deficiency With or Without Anemia
por: Li, Yihang, et al.
Publicado: (2022)

Dapagliflozin Improves Erythropoiesis and Iron Metabolism in Type 2 Diabetic Patients with Renal Anemia
por: Osonoi, Takeshi, et al.
Publicado: (2023)

Implantation of dedifferentiated fat cells ameliorated antineutrophil cytoplasmic antibody glomerulonephritis by immunosuppression and increases in tumor necrosis factor-stimulated gene-6
por: Utsunomiya, Kei, et al.
Publicado: (2022)

Euglycemic diabetic ketoacidosis caused by canagliflozin: a case report
por: Fukuda, Masafumi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7nq8n99eg9ghso4qrdupaf4bok